Scientists at the University of Calcutta and the Saroj Gupta Cancer Care and Research Institute (SGCC & RI), Kolkata propose a novel strategy to fight the aggressive triple negative breast cancer using combinatorial therapy of their new techniques along with conventional drugs.
Dr. Chatterji and her team in their study compared normal and breast cancer stem cells (brCSCs) to identify new mechanisms that make these brCSCs more resistant to drugs. Stem cells are the cells that have the capability to form into any other type of cell or divide into more stem cells. The brCSCs are resistant to drugs, live longer and make more cancer cells once the chemotherapy regimen is finished and thus re-form the tumor.
“Astonishingly this population of brCSCs are seen to increase significantly when chemotherapy is given to patients, thereby increasing the risk of tumor recurrence”, as observed by Pritha Mukherjee, a graduate student in the lab. and lead author of the publication. “This is primarily because of persistence and impetuous proliferation of the cancer stem cells which do not get eliminated by conventional chemotherapy because of elevated expression of drug efflux pumps”- pumps that throw out the drugs from the cell.
The researchers identified molecules that played key roles in chemo resistance and migration as SOX2, ABCG2, and TWIST1. They showed that on shutting down SOX2 which further affects TWIST1 and treating with the conventional anti-cancer drug, paclitaxel (Pax) resulted in the restricted migration of the cells. Remarkably, even after removal of the drug, Pax, the cells did not migrate. These results were published in the August 2017 issue of Scientific Reports.
The authors suggest, “obliterating SOX2 expression specifically in brCSCs before or during chemotherapy is a possible approach to eliminate the brCSC population within a tumor, with a promise to prevent post-chemotherapy recurrences in future”.
“A treatment strategy which ensures eradication of persistent drug resistant cells would serve as a complete therapy”, says Dr. Arnab Gupta, Director, SGCC & RI.
Breast cancer is the most commonly diagnosed cancer in the world. It threatens 1 in every 28 urban women in India. Triple negative breast cancer (TNBC) is a subset of breast cancer which is resistant to most drugs and tends to recur once the drugs are removed. In addition, this cancer is particularly aggressive & spreads easily.
“Unlike patients who may respond to hormone or trastuzumab administration, TNBC patients are generally given intense adjuvant cycles of chemotherapy in addition to radiation where indicated. However, the risk of disease recurrence still persists”, Dr. Gupta told India Science Wire.
Prof. Urmi Chatterji, University of Calcutta says, “The clinical part of our study has figured out that TNBC evolves to be of prominent occurrence, especially in patients from West Bengal and Bangladesh. Despite recent advances in the treatment of triple negative breast tumors, tumor metastasis and the incidence of distant relapse remains high, necessitating novel therapies to surmount the existing paradigm”.
“Approaches should be taken to overcome the resistance phenomenon of the cancer stem cells, chiefly by making them sensitive to drugs to which they were resistant. Therefore, designing new methods which would target SOX2 would in effect render the resistant population sensitive to anti-cancer drugs. The outcome of this basic research may in future be translated into a clinical methodology for controlling tumor recurrence”, suggests Prof. Dhrubajyoti Chattopadhyay, Vice Chancellor, Amity University, an author of the publication.
“Further research by Dr. Sreemanti Das, a post-doc in the laboratory, has identified nanoformulations of anti-cancer drugs which have the potential to reduce SOX2 expression and effectively obliterate the cancer stem cell population, not only in cells in culture but also in tumors induced in mice, and thereby has immense potential in being developed as a promising drug in future”, confirmed Prof. Chatterji.
Although there is a long road ahead consisting of studies and clinical trials which need to be performed before such a treatment option is available, the current study holds promise. If the study manages to lead to a treatment protocol, cancer survivors will no longer have to live in the fear of their cancer coming back.
The research team led by Dr. Urmi Chatterji, included of Pritha Mukherjee, Arnab Gupta, and Dhrubajyoti Chattopadhyay. The study was funded by Department of Biotechnology, Government of India.


